Invest in Allogene Therapeutics Inc. (ALLO) to keep your portfolio healthy

The price of Allogene Therapeutics Inc. (NASDAQ: ALLO) closed at $6.55 in the last session, up 2.83% from day before closing price of $6.37. In other words, the price has increased by $+0.18 from its previous closing price. On the day, 1321215 shares were traded. ALLO stock price reached its highest trading level at $6.63 during the session, while it also had its lowest trading level at $6.33.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…



We take a closer look at ALLO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 11.60 and its Current Ratio is at 11.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

On December 12, 2022, BofA Securities Downgraded its rating to Underperform which previously was Buy and also lowered its target price recommendation from $24 to $9.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 17 when Bhavnagri Veer sold 3,000 shares for $7.04 per share. The transaction valued at 21,120 led to the insider holds 580,677 shares of the business.

Bhavnagri Veer sold 5,602 shares of ALLO for $42,186 on Dec 15. The General Counsel now owns 583,677 shares after completing the transaction at $7.53 per share. On Aug 12, another insider, WITTE OWEN N., who serves as the Director of the company, sold 5,000 shares for $17.25 each. As a result, the insider received 86,250 and left with 218,271 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 4592.86 while its Price-to-Book (P/B) ratio in mrq is 1.27.

Stock Price History:

Over the past 52 weeks, ALLO has reached a high of $17.49, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is 7.95, while the 200-Day Moving Average is calculated to be 10.33.

Shares Statistics:

According to the various share statistics, ALLO traded on average about 1.88M shares per day over the past 3-months and 1.92M shares per day over the past 10 days. A total of 143.66M shares are outstanding, with a floating share count of 82.54M. Insiders hold about 0.60% of the company’s shares, while institutions hold 76.20% stake in the company. Shares short for ALLO as of Oct 13, 2022 were 30.05M with a Short Ratio of 33.43M, compared to 22.22M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 20.90% and a Short% of Float of 33.46%.

Earnings Estimates

The company has 18 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.64 for the current quarter, with a high estimate of -$0.53 and a low estimate of -$0.91, while EPS last year was -$0.57. The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.5 and low estimates of -$0.95.

Analysts are recommending an EPS of between -$2.14 and -$2.65 for the fiscal current year, implying an average EPS of -$2.45. EPS for the following year is -$2.85, with 18 analysts recommending between -$2.13 and -$3.36.